Discovery of Inhibitors of DNA Methyltransferase 2, an Epitranscriptomic Modulator and Potential Target for Cancer Treatment-Reference-Cited by-同舟云学术

Discovery of Inhibitors of DNA Methyltransferase 2, an Epitranscriptomic Modulator and Potential Target for Cancer Treatment

Published:2022-07-18 Issue:14 Volume:65 Page:9750-9788
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Schwickert Marvin¹^ORCID,Fischer Tim R.¹,Zimmermann Robert A.¹,Hoba Sabrina N.¹,Meidner J. Laurenz¹,Weber Marlies¹,Weber Moritz¹,Stark Martin M.¹,Koch Jonas²^ORCID,Jung Nathalie³,Kersten Christian¹^ORCID,Windbergs Maike³,Lyko Frank²,Helm Mark¹^ORCID,Schirmeister Tanja¹

Affiliation:

1. Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University Mainz, Staudinger Weg 5, D-55128 Mainz, Germany

2. Division of Epigenetics, DKFZ-ZMBH Alliance, German Cancer Research Center, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany

3. Institute of Pharmaceutical Technology and Buchmann Institute for Molecular Life Sciences, Goethe University Frankfurt, Max-von-Laue-Str. 9, D-60438 Frankfurt am Main, Germany

Funder

Deutsche Forschungsgemeinschaft

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c00388

Reference95 articles.

1. The timeline of epigenetic drug discovery: from reality to dreams

2. The RNA modification landscape in human disease

3. Epigenetic inheritance of acquired traits through sperm RNAs and sperm RNA modifications